Drug Trial Radar · NCT05249556
Open-label, Single-arm Trial of Ganaxolone in CDD Patients 6 Months to Less Than 2 Years Old
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Mar 2027
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Immedica Pharma ABIndustry
- Sponsor type
- Industry
- First posted
- Feb 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months, up to 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn how patients with CDKL-5 deficiency disorder (CDD) aged 6 months to 2 years of age respond to treatment with ganaxolone. The main questions the trial aims to answer are: * The amount of the medicine that was in participants' bodies and the safety of the medicine. * Does the medicine ganaxolone lower the number of seizures when used in addition to the participant's usual anti-seizure treatment. Participants will: Take ganaxolone 3 times daily for up to 52 weeks. Visit the clinic every 3 to 5 weeks for the initial 17 weeks of the trial and thereafter every 11 to 12 weeks. The participant's caregiver will: Keep a daily diary of the participants seizures and use of anti-seizure medications, including the trial drug ganaxolone.
Conditions
- CDKL5 Deficiency Disorder
Interventions
GanaxoloneDrug
Ganaxolone
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ganaxolone exposure in participants receiving ganaxolone doses up to 63 mg/kg/dayTime frame: Baseline through 17 weeks
- Ganaxolone exposure in participants receiving ganaxolone doses up to 63 mg/kg/dayTime frame: Baseline through 17 weeks
- Ganaxolone exposure in participants receiving ganaxolone doses up to 63 mg/kg/dayTime frame: Baseline through 17 weeks
- Safety and tolerability of ganaxolone as adjunctive therapy for the treatment of seizures in participants receiving ganaxolone doses up to 63 mg/kg/dayTime frame: Baseline through to 52 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.